File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Recommendations and potential future options in the treatment of hepatitis B

TitleRecommendations and potential future options in the treatment of hepatitis B
Authors
Issue Date2006
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eop
Citation
Expert Opinion On Pharmacotherapy, 2006, v. 7 n. 16, p. 2225-2231 How to Cite?
AbstractThe natural history of chronic hepatitis B should be clearly defined before appropriate recommendations for treatment can be advocated. In patients who acquire the disease in early life, the complications of chronic hepatitis B continue to occur as a result of prolonged insidious damage to the liver, even in the low viraemic phase. Treatment that ends with hepatitis B e antigen seroconversion with hepatitis B virus DNA levels just below 105 copies/ml may not be sufficient. Patients with mild elevation of alanine aminotransferase levels are already at considerable risk of developing complications. Treatment strategy should aim at maximal and prolonged viral suppression to the lowest possible hepatitis B virus DNA levels. Nucleotide/nucleoside analogues will become the mainstay of treatment. Future treatment strategic plans should target maximising antiviral potency and minimising the chance of drug resistance. © 2006 Informa UK Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/78468
ISSN
2015 Impact Factor: 3.543
2015 SCImago Journal Rankings: 0.884
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:43:13Z-
dc.date.available2010-09-06T07:43:13Z-
dc.date.issued2006en_HK
dc.identifier.citationExpert Opinion On Pharmacotherapy, 2006, v. 7 n. 16, p. 2225-2231en_HK
dc.identifier.issn1465-6566en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78468-
dc.description.abstractThe natural history of chronic hepatitis B should be clearly defined before appropriate recommendations for treatment can be advocated. In patients who acquire the disease in early life, the complications of chronic hepatitis B continue to occur as a result of prolonged insidious damage to the liver, even in the low viraemic phase. Treatment that ends with hepatitis B e antigen seroconversion with hepatitis B virus DNA levels just below 105 copies/ml may not be sufficient. Patients with mild elevation of alanine aminotransferase levels are already at considerable risk of developing complications. Treatment strategy should aim at maximal and prolonged viral suppression to the lowest possible hepatitis B virus DNA levels. Nucleotide/nucleoside analogues will become the mainstay of treatment. Future treatment strategic plans should target maximising antiviral potency and minimising the chance of drug resistance. © 2006 Informa UK Ltd.en_HK
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eopen_HK
dc.relation.ispartofExpert Opinion on Pharmacotherapyen_HK
dc.rightsExpert Opinion on Pharmacotherapy. Copyright © Informa Healthcare.en_HK
dc.subject.meshAsia - epidemiologyen_HK
dc.subject.meshEurope - epidemiologyen_HK
dc.subject.meshForecastingen_HK
dc.subject.meshHepatitis B, Chronic - drug therapy - epidemiology - immunology - virologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshSocieties, Medicalen_HK
dc.subject.meshUnited States - epidemiologyen_HK
dc.titleRecommendations and potential future options in the treatment of hepatitis Ben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1465-6566&volume=7&issue=16&spage=2225&epage=2231&date=2006&atitle=Recommendations+and+Potential+Future+Options+in+the+Treatment+of+Hepatitis+Ben_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/14656566.7.16.2225en_HK
dc.identifier.pmid17059379en_HK
dc.identifier.scopuseid_2-s2.0-39049185674en_HK
dc.identifier.hkuros130678en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-39049185674&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume7en_HK
dc.identifier.issue16en_HK
dc.identifier.spage2225en_HK
dc.identifier.epage2231en_HK
dc.identifier.isiWOS:000241643900004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.citeulike916146-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats